Over the past year there were no insider purchases at Royalty Pharma plc. Five insiders sold roughly $92.8 million instead.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
On the institutional side, 643 funds reported holding RPRX at the end of Q2 2026, and more funds bought than sold. 5 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Urist Marshall | Executive Officer | Sell | 4,126 | $57.10 | $236K | SEC |
| Sep 30, 2026 | Urist Marshall | Executive Officer | Sell | 4,126 | $57.88 | $239K | SEC |
| Sep 24, 2026 | Hite Christopher | Chair | Sell | 96,073 | $58.51 | $5.6M | SEC |
| Sep 24, 2026 | Hite Christopher | Chair | Sell | 3,927 | $58.93 | $231K | SEC |
| Aug 19, 2026 | Hite Christopher | Chair | Sell | 100,000 | $59.97 | $6.0M | SEC |
| Aug 17, 2026 | Coyne Terrance P. | CFO | Sell | 9,230 | $58.59 | $541K | SEC |
| Aug 17, 2026 | Coyne Terrance P. | CFO | Sell | 1,772 | $59.14 | $105K | SEC |
| Jul 2, 2026 | Urist Marshall | Executive Officer | Sell | 9,099 | $55.88 | $508K | SEC |
| Jul 2, 2026 | Hite Christopher | Chair | Sell | 2,554 | $57.10 | $146K | SEC |
| Jul 2, 2026 | Hite Christopher | Chair | Sell | 97,446 | $56.50 | $5.5M | SEC |
| Jul 2, 2026 | Hite Christopher | Chair | Sell | 600 | $57.09 | $34K | SEC |
| Jul 2, 2026 | Hite Christopher | Chair | Sell | 29,400 | $56.44 | $1.7M | SEC |
| Jun 25, 2026 | Urist Marshall | Executive Officer | Sell | 9,098 | $55.18 | $502K | SEC |
| Jun 25, 2026 | Hite Christopher | Chair | Sell | 117,592 | $54.47 | $6.4M | SEC |
| Jun 25, 2026 | Hite Christopher | Chair | Sell | 32,408 | $54.11 | $1.8M | SEC |
In the last 12 months Royalty Pharma plc insiders made open-market purchases worth about $0 and sales worth about $92.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in RPRX was filed on 2026-10-05.
643 investment managers reported holding RPRX in SEC Form 13F filings for Q2 2026.
No congressional trades in RPRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).